Stillcanna J.V. Extraction Facility in Romania Awaits Final Approvals

The Company Releases the First of a Videos Series Highlighting the Facility

Vancouver, British Columbia – (PR Newswire) – Monday July 22, 2019) – Stillcanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce that it has reached the final stages of the licensing process for its ORIGIN extraction facility in Romania. The project is a Joint Venture with its U.K. based partner Dragonfly Biosciences

“The stage is set for full commercial operations of the Company’s Romanian facility,” stated Jason Dussault CEO of Stillcanna. “Both Stillcanna and our partner Dragonfly are focused on the final approvals required to begin full commercial operations, we anticipate licensing completion and full production within the 4th quarter of 2019.

“Our closed loop ethanol extraction system is designed to run continuously from hemp wash, winterization, filtration, distillation and back again,” explained Shae de Jaray, COO and Chief Engineer of Stillcanna. “The designed system is ready for large scale extraction as soon as we receive our license, I couldn’t be happier with our system.”

They say a picture is worth a thousand words. To showcase the Romanian facility ORIGIN the Company has produced a series of short videos. The first video of the series “The Origin Project” is available at http://theStillcannareport.com. Further videos in the series will be published over the next few weeks.

Previously on July 16, 2019 the Company stated that it expected to harvest 350 kilos of dried flower per hectare from its 1500 hectares, for a total yield of 525,000 kilos of flower. The Company estimated the CBD yield to be approximately 36,000 kilos at 7% CBD content by volume, but had printed 5% content in its release. The Company’s proprietary hemp varietal has consistently achieved 7% CBD content by volume.

On Behalf of the Board
Jason Dussault, CEO

 

Fabrice Taylor discusses StillCanna

Fabrice Taylor, publisher of The President’s Club Investment Letter, discusses StillCanna.

Click Here To Watch

Stillcanna’s Polish Operations in Final Stages of Crop Rotation

Company’s Agricultural Team Predicts up to 525,000 Kilos of Flower

Vancouver, British Columbia – (PR Newswire) – Tuesday July 16, 2019) – Stillcanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA)(“STIL” or the “Company”) is pleased to announce that its Polish agricultural team is in the final stages of crop rotation

In managing 1500 hectares of hemp, the planting, maintenance and harvesting are carefully planned to maximize the Company’s agricultural equipment. The Company plants and harvests in stages, with planting happening over a 60-day period and harvesting happening over a 60-day period. The Olimax team in Poland is actively working on the last of its planting cycle while preparing for the beginning of its harvest cycle in the next few weeks.

The Company’s proprietary hemp varietal has a 50-day growth cycle to harvest, this fast growing varietal allows for easy crop rotation and management, with the possibility of two crops per year.

As previously stated on June 14, 2019 the Company is expecting 350 kilos of dried flower per hectare from its 1500 hectares, for a total yield of 525,000 kilos of flower. Should the flower contain hold 5% CBD by volume then the Company has the potential to yield over 36,000 kilos of CBD. The Company anticipates bulk pricing of CBD isolate in large volumes will average C$5,000 per kilo.

The Company’s Nexus extraction facility in Poland is on time and on budget, the Company expects the facility to be in production Q4 to begin fulfilling its sales commitments.

“Our team continues to be focused on the tasks at hand,” stated Jason Dussault CEO of Stillcanna. “The culmination of our teams efforts should be apparent in the 4thquarter and we achieve our harvesting, extraction and sales milestones.”

About Stillcanna Inc.

Stillcanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of its Polish extraction facilities, Stillcanna will be one of the largest processors and providers of market ready CBD in Europe.

On Behalf of the Boar

Joel Leonard
Chief Financial Officer

CONTACT:

Mauricio Inzunza
Mauricio@stillcanna.com
1(844)-442-STILL (7845)

 

Stillcanna Founder Relocates to Europe to Concentrate on Bulk CBD Sales

VANCOUVER, July 10, 2019 /CNW/ – Stillcanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce its founder Marc Crimeni is relocating to Europe to concentrate on bulk sales of the Company’s CBD products.

“We are a global company operating in multiple time zones,” stated Jason Dussault CEO of Stillcanna. “Marc has spent the majority of his career in global sales and marketing having done business in over 60 countries.  His sales and marketing knowledge across a myriad of products over the past 4 decades is instrumental in Stillcanna achieving its corporate milestones, I applaud Marc’s dedication to the task at hand.”

“In the near term the European market for bulk CBD has been forecast to be the largest in the world,” explained Marc Crimeni. “Capitalizing on this opportunity is difficult when faced with an 8 to 10 hour time difference. In founding the Company it was important to me to secure the right team members in management, agriculture, harvesting and extraction so I could concentrate on my core skills in international sales, today we have reached that milestone. I look forward to operating in the same time zone as our facilities and future customers while assisting the Company on achieving its revenue goals moving forward.”

Mr. Crimeni will be relocating to Europe at the end of July 2019.

About Stillcanna Inc.

Stillcanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe. The company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of its Polish extraction facilities, Stillcanna will be one of the largest processors and providers of market ready CBD in Europe.

On Behalf of the Board

Joel Leonard
Chief Financial Officer

Stillcanna Strengthens Board with the Appointment of William Macdonald as Director

VANCOUVER, June 19, 2019 /PRNewswire/ – Stillcanna Inc. (CSE: STIL OTC:SCNNF, FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce the appointment of William (Bill) Macdonald as an independent member of the Company’s Board of Directors.

Mr. Macdonald will be an asset to the Company by providing assistance navigating the Company’s regulatory and legal obligations.  Mr. Macdonald will use his decades of knowledge and experience in the public markets to add a greater depth of knowledge to the Board.

“Mr. Macdonald is a well-respected name in the public markets,” stated Jason Dussault CEO, “we are excited to add Mr. Macdonald to the board and look forward to receiving his sound advice and direction when navigating regulatory issues.”

Mr. Macdonald is a founder and principal of Macdonald Tuskey, Corporate and Securities Lawyers, a boutique securities and corporate finance firm located in Vancouver, British Columbia and established in 2008.  Mr. Macdonald also has public market experience as a director for several public companies listed on the TSX Venture Exchange.

In conjunction with the appointment of Mr. Macdonald as director, Denis Semenov will be stepping down from his position as director.  The Company wishes to thank Mr. Semenov for his contributions to the Company and wish him all the best on his future endeavors.

About Stillcanna Inc.

Stillcanna Inc. (CSE: STIL) www.Stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.

On Behalf of the Board,

Jason Dussault,
Chief Executive Officer and Director
Email: info@Stillcanna.com
Phone: 604-239-0840

Stillcanna Predicts Bumper Hemp Crop in Poland resulting in Hemp Offtake LOI with Sequoya Cannabis

VANCOUVERJune 14, 2019 /PRNewswire/ – Stillcanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce that favorable weather conditions and above average temperatures in Poland is having a positive effect on its current hemp crop.  The Company’s agricultural experts at Olimax in Poland are anticipating harvesting more biomass from its 1,500-hectare crop than previously expected. Originally, the Company anticipated harvesting 250 kilograms of dry flower per hectare, but the Company now expects to harvest 350 kilograms of dry flower per hectare.  Hemp, unlike many other crops, thrives in a hot dry climate and Poland has been experiencing warmer than usual weather.

As was previously announced on May 28, 2019, Stillcanna’s Polish extraction facility was engineered to process 250 kilograms of dry flower per hectare this year. With an excess of 70,000 kilos of dry flower expected for 2019 comes the opportunity to monetize this excess. Stillcanna has signed a letter of intent with Sequoya Cannabis to provide Sequoya with C$1,000,000 worth of hemp off its fields. The companies intend to sign a definitive agreement by July 15, 2019 and will announce details of the definitive agreement once it is signed.

“There is a shortage of both CBD and good biomass in Europe,” stated Jason Dussault CEO of Stillcanna. “It is anticipated that favorable agricultural conditions will allow us to meet or exceed our own biomass requirements while quickly monetizing the 2019 excess. This order represents only a portion of our available excess biomass for 2019.”

“Having access to surplus biomass from Stillcanna’s Polish fields is a definite win-win for both companies,” explained Shemek Fedyczkowski, CEO of Sequoya Cannabis. “To find quality biomass so close to our Krakow facility is amazing, I hope we build a long term relationship with Stillcanna and that they will allow us to buy more hemp in the future.”

The Company has also entered into an agreement with FlinnWest Solutions to enhance public awareness of the Company with a budget of approximately $840,000 US.  FlinnWest Solutions are experts in digital advertising, paid distribution, media buying and content creation.

Visit http://thestillcannareport.com for additional company information.

About Stillcanna Inc.

Stillcanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry. 

On Behalf of the Board, 

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com
Phone: 778-838-3692

StillCanna Enters into a Strategic Relationship with CBD Logistics Expert for Secure Transportation of its Products Internationally

VANCOUVERJune 5, 2019 /CNW/ – StillCanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce it has entered a strategic relationship with Sarah Yetman, an expert in the international transportation of industrial hemp and CBD.

Ms. Yetman has overseen the shipment of tens of thousands of kilograms of CBD into the USA and other countries. Ms. Yetman is also active in the supply of CBD products and biomass globally and will be representing StillCanna products to her existing customer base.

Ms. Yetman will be responsible for:

  • Arranging the shipment of biomass and CBD isolate and CBD distillate internationally;
  • Arranging all applicable insurance policies and required certificates of origin;
  • Organizing the clearance of shipments with the applicable Drug Enforcement Administration officials and customs officials;
  • Organizing the delivery of the CBD product to end customers once the CBD product has cleared customs; and
  • Organizing the product handling and testing at its final destination.

Ms. Yetman has been able to import products into the USA based sovereign ports of call and clear those products through customs using her existing relationships with both the Drug Enforcement Administration officials and US Customs officials.

“We are very impressed with the infrastructure that Sarah has been able to establish in both the USA and abroad,” stated Jason Dussault, CEO of StillCanna. “Her expertise and experience provides an invaluable service to StillCanna and is an important link in our supply chain. This relationship allows our products to reach a wider international audience. Ms. Yetman also brings a broad international base of buyers for both CBD products and hemp biomass.”

“I couldn’t be more pleased to be working with StillCanna and providing them with the global logistics they require,” said Sarah Yetman. “The contacts and infrastructure I have established is a custom fit for both the Company and myself.  I look forward to implementing and overseeing the first of many shipments.”

StillCanna Announces OTC Markets Listing

VANCOUVER, May 31, 2019 /CNW/ – StillCanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce that it is trading on the OTC Markets under the symbol “SCNNF” and its shares are DTC Eligible. StillCanna’s shares are also quoted on the Börse Frankfurt Exchange in Germany under the symbol “A2PEWA” in addition to the Canadian Securities Exchange (CSE) under the symbol “STIL”.

“Trading on the US OTC Markets will assist us with increasing our U.S. shareholder base and investor awareness as we complete our transition into producing high-quality CBD Isolate from our production centres in Romania and Poland,” stated Jason Dussault, Chief Executive Officer, “having recently announced a C$36 million supply agreement with a leading US-based producer of CBD-infused products, we look to increase our visibility with both US customers and shareholders alike.”

What is DTC Eligibility?

DTC Eligibility means that a public company’s securities are able to be deposited through DTC.  DTC is the largest securities depository in the world and holds over $35 trillion dollars’ worth of securities on deposit. DTC accepts deposits of securities from its participants only, who are usually clearing firms. Most brokers clear stock in-house or hire a clearing firm to do so on their behalf. All movements of securities are made to the participant’s account electronically with book-entry adjustments. If an issuer is not DTC eligible, then its shares cannot be transferred between brokerage accounts electronically, which means its shares cannot be traded easily.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europeto be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry. 

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

StillCanna Strengthens Board with Business and Finance Veteran Warren Robinson

VANCOUVERMay 30, 2019 /PRNewswire/ – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce the appointment of Warren Robinson to its Board of Directors. In conjunction with the appointment of Mr. Robinson as director, the Company’s CFO Joel Leonard has resigned from the Board of Directors.  Mr. Leonard will continue to operate as the Company’s CFO.

Mr. Robinson will assist StillCanna in its capital markets activities as well as in identifying global expansion initiatives.  Mr. Robinson will use his wealth of knowledge and experience to help with increasing the Company’s reach amongst institutional investors and provide the Company with a greater depth of expertise in corporate finance, capital raising/structuring, and mergers & acquisitions activity.

“Mr. Robinson is a proven deal originator with decades of experience in financing and advising growth companies,” stated Jason Dussault CEO, “we are excited to have an active board member like Mr. Robinson to help initiate further growth opportunities for StillCanna.”

Mr. Robinson is CEO of Atlas Capital Inc., an Exempt Market Dealer, which is registered to operate in British ColumbiaAlbertaSaskatchewanManitobaOntario and Quebec.  Atlas is a hybrid firm, with the ability to operate in diversified sectors and has a pool of investors and relationships that enable a merchant style of approach to dealings. Mr. Robinson has spent his career in institutional finance including advising, SAF Group, a Private Equity firm with over $1.5 billion in active investments.  From 2009 to 2014 Mr. Robinson was Managing Director at Haywood Securities, an investment dealer.  Prior to working at Haywood, Mr. Robinson was a Partner at Tristone Capital, a Calgary based energy boutique, that was acquired by Macquarie Capital in 2009.

“I believe StillCanna has an early leadership position in the European marketplace and the industry opportunity in Europeis extensive.  I am very excited to be working with Jason and the StillCanna team as we develop the business as well as explore international partnerships and acquisitions,” commented Mr. Robinson.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.

StillCanna Signs Definitive Agreement With BioSciences Enterprises to Supply C$36 Million Worth of CBD Isolate and Implements a Two-Stage Extraction Plan for Poland

VANCOUVER, May 28, 2019 /PRNewswire/ – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce that further to its press release dated March 28, 2019, it has signed a definitive agreement to supply Bioscience Enterprises of California with up to C$36,000,000 worth of CBD Isolate.

“We are extremely pleased to formalize our relationship with StillCanna,” stated Richard Parker President of Biosciences Enterprises, “not a day goes by that our firm isn’t looking for a company like StillCanna, but finding a knowledgeable seed to shelf CBD manufacturer in this young industry is extremely rare. With access to their own biomass and years of extraction expertise StillCanna makes a perfect partner for us today and into the future.”

To accelerate its product delivery, the Company is implementing a two-stage extraction plan for Poland. Stage one will consist of equipment engineered to optimize the production of CBD Isolate. With permitting in place and equipment ordered for Poland, it is anticipated that the initial line will produce and ship CBD Isolate Q4 of 2019 allowing the Company to begin fulfilling its obligations under the Biosciences agreement.

“One of the many benefits in our acquisition of Olimax in Poland is its infrastructure including buildings and existing licenses to extract CBD. By having these licenses in place, Olimax alleviates what could be a lengthy bureaucratic process to obtain such licenses. The purchase and installation of equipment is not the delaying factor in building an extraction facility in Europe, it’s the time required to obtain the many licenses and permits to manufacture CBD,” explained Jason Dussault Chief Executive Officer of StillCanna, “the Company is ecstatic about being able to hit the ground in Poland running.”

Stage two of the Company’s extraction plan in Poland is a brand new, ground up, GMP certified CBD extraction facility engineered to produce over 80 million grams of CBD per year. The Company has budgeted an initial C$8.5 million for construction and equipment. Completion of stage two in Poland is expected to be completed in 10 to 14 months.

Since the Company’s initial financing in October 28, 2018 it has been focused on the building and completion of its Romanian extraction facility.  Originally, the Company had anticipated a 12 to 14 month build to be fully operational. The Company remains on time and on budget. Over the past 7 months the Company has:

  • Secure the physical location;
  • Completed all architectural drawings, electrical drawing and fire plan;
  • Updated the architectural drawings to be GMP complaint;
  • Ordered, installed and wired all the equipment required to produce CBD;
  • Processed tons of hemp and have stored tons of flower waiting final processing;
  • Purchased and received all laboratory equipment for testing and chromatography;
  • Completed construction on a minus 26 degree, 400 square foot walk in freezer;
  • Secured leading Chemists and PhDs to oversee production;
  • Built GMP compliant facility including special floors, ceiling, walls, lights doors and ventilation;
  • Achieved a major milestone by receiving final approval from the Environmental Protection Agency;
  • Completed our GMP Standard Operating Procedures

The Company’s equipment and personnel have been in place in Romania for many months as we anxiously await our final permits to manufacture CBD. The Company expects that it will receive all required licenses and permits and be in full production within its original 12-month timeline. The Company is waiting for certain approvals including, but not limited to:

  • The Romanian General Inspectorate for Emergency Situations;
  • A Geotechnical Report;
  • Health Ministry Approval; and
  • Final Fire Inspection.

The Company expects to receive all remaining approvals required to be obtained in its normal course of business without complication.

The Company looks forward to manufacturing and shipping CBD to meet the needs of its current and future partners.

The Company is also pleased to announce 1,800,000 stock options have been granted to certain officers and consultants pursuant to the Company’s stock option plan.  The options are exercisable after three months from the grant date for a period of five years at a price of $1.23 per share.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europeto be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.